Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 17Recruiting 12Unknown 9Terminated 8Withdrawn 3Suspended 2Not yet recruiting 2Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2Recurrence 1

Interventions

Specimen Handling 12Magnetic Resonance Spectroscopy 10Cyclophosphamide 10Cisplatin 7Bevacizumab 7pembrolizumab 6Radiosurgery 6Oxaliplatin 5Nivolumab 5Irinotecan 5Fluorouracil 5Everolimus 5Capecitabine 5Biopsy 5venetoclax 4fludarabine 4S 1 (combination) 4Prednisone 4Leucovorin 4Gemcitabine 4Etoposide 4Drug Therapy 4Doxorubicin 4Azacitidine 4fludarabine phosphate 3Vincristine 3Taxes 3Tacrolimus 3Surveys and Questionnaires 3Surgical Procedures, Operative 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × OTHER × Propranolol × Clear all
NCT03384836 2025-07-02

Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery

Roswell Park Cancer Institute

Phase 1/2 Suspended
47 enrolled
Dermatologic

Melanoma

NCT01988831 2019-05-10

Efficacy of Propranolol Treatment to Prevent Melanoma Progression

University Hospital, Geneva

Phase 2 Suspended
450 enrolled
Dermatologic

Melanoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡